Prevention and Therapy of Prostate Cancer: An Update on Alternatives for Treatment and Future Perspectives

Author(s): Fernanda Majolo, Bruna Caye, Stefani Natali Stoll, Juliano Leipelt, Ana Lúcia Abujamra, Márcia Inês Goettert*

Journal Name: Current Drug Therapy

Volume 15 , Issue 3 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Prostate cancer is one of the most prevalent cancer types in men worldwide. With the progression of the disease to independent stimulation by androgen hormones, it becomes more difficult to control its progress. In addition, several studies have shown that chronic inflammation is directly related to the onset and progression of this cancer. For many decades, conventional chemotherapeutic drugs have not made significant progress in the treatment of prostate cancer. However, the discovery of docetaxel yielded the first satisfactory responses of increased survival of patients. In addition, alternative therapies using biomolecules derived from secondary metabolites of natural products are promising in the search for new treatments. Despite the advances in the treatment of this disease in the last two decades, the results are still insufficient and conventional therapies do not present the expected results they once promised. Thus, a revision and (re)establishment of prostate cancer therapeutic strategies are necessary. In this review, we also approach suggested treatments for molecular biomarkers in advanced prostate cancer.

Keywords: Prostate cancer, inflammation, natural products, treatment, biomarkers, docetaxel.

[1]
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5): E359-86.
[http://dx.doi.org/10.1002/ijc.29210] [PMID: 25220842]
[2]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65(1): 5-29.
[http://dx.doi.org/10.3322/caac.21254] [PMID: 25559415]
[3]
DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014; 64(4): 252-71.
[http://dx.doi.org/10.3322/caac.21235] [PMID: 24890451]
[4]
Daniyal M, Siddiqui ZA, Akram M, Asif HM, Sultana S, Khan A. Epidemiology, etiology, diagnosis and treatment of prostate cancer. Asian Pac J Cancer Prev 2014; 15(22): 9575-8.
[http://dx.doi.org/10.7314/APJCP.2014.15.22.9575] [PMID: 25520069]
[5]
Whittemore AS, Kolonel LN, Wu AH, et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 1995; 87(9): 652-61.
[http://dx.doi.org/10.1093/jnci/87.9.652] [PMID: 7752270]
[6]
Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991; 63(6): 963-6.
[http://dx.doi.org/10.1038/bjc.1991.210] [PMID: 2069852]
[7]
De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7(4): 256-69.
[http://dx.doi.org/10.1038/nrc2090] [PMID: 17384581]
[8]
Gurel B, Lucia MS, Thompson IM Jr, et al. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2014; 23(5): 847-56.
[http://dx.doi.org/10.1158/1055-9965.EPI-13-1126] [PMID: 24748218]
[9]
Doat S, Cénée S, Trétarre B, et al. Nonsteroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk: results from the EPICAP study. Cancer Med 2017; 6(10): 2461-70.
[http://dx.doi.org/10.1002/cam4.1186] [PMID: 28941222]
[10]
Sfanos KS, De Marzo AM. Prostate cancer and inflammation: the evidence. Histopathology 2012; 60(1): 199-215.
[http://dx.doi.org/10.1111/j.1365-2559.2011.04033.x] [PMID: 22212087]
[11]
Abdelgadir SE, Connolly PB, Resko JA. Androgen binding in peripheral tissues of fetal rhesus macaques: effects of androgen metabolism in liver. J Steroid Biochem Mol Biol 1990; 37(4): 545-51.
[http://dx.doi.org/10.1016/0960-0760(90)90399-6] [PMID: 2278838]
[12]
Bousset L, Rambur A, Fouache A, et al. New insights in prostate cancer development and tumor therapy: modulation of nuclear receptors and the specific role of liver x receptors. Int J Mol Sci 2018; 19(9): pii: E2545.
[http://dx.doi.org/10.3390/ijms19092545] [PMID: 30154328]
[13]
Crumbaker M, Khoja L, Joshua AM. AR signaling and the PI3K pathway in prostate cancer. Cancers (Basel) 2017; 9(4): 1-15.
[http://dx.doi.org/10.3390/cancers9040034] [PMID: 28420128]
[14]
Wise HM, Hermida MA, Leslie NR. Prostate cancer, PI3K, PTEN and prognosis. Clin Sci (Lond) 2017; 131(3): 197-210.
[http://dx.doi.org/10.1042/CS20160026] [PMID: 28057891]
[15]
Nevedomskaya E, Baumgart SJ, Haendler B. Recent advances in prostate cancer treatment and drug discovery. Int J Mol Sci 2018; 19(5): pii: E1359.
[http://dx.doi.org/10.3390/ijms19051359] [PMID: 29734647]
[16]
Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18(1): 11-22.
[http://dx.doi.org/10.1016/j.ccr.2010.05.026] [PMID: 20579941]
[17]
Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 2006; 4(4): 221-33.
[http://dx.doi.org/10.1158/1541-7786.MCR-05-0261] [PMID: 16603636]
[18]
Denkert C, Thoma A, Niesporek S, et al. Overexpression of cyclooxygenase-2 in human prostate carcinoma and prostatic intraepithelial neoplasia-association with increased expression of Polo-like kinase-1. Prostate 2007; 67(4): 361-9.
[http://dx.doi.org/10.1002/pros.20467] [PMID: 17265445]
[19]
Giampietri C, Petrungaro S, Padula F, et al. Autophagy modulators sensitize prostate epithelial cancer cell lines to TNF-alpha-dependent apoptosis. Apoptosis 2012; 17(11): 1210-22.
[http://dx.doi.org/10.1007/s10495-012-0752-z] [PMID: 22923157]
[20]
Lee SH, Jeong D, Han Y-S, Baek MJ. Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis. Ann Surg Treat Res 2015; 89(1): 1-8.
[http://dx.doi.org/10.4174/astr.2015.89.1.1] [PMID: 26131438]
[21]
Sciarra A, Di Silverio F, Salciccia S, Autran Gomez AM, Gentilucci A, Gentile V. Inflammation and chronic prostatic diseases: evidence for a link? Eur Urol 2007; 52(4): 964-72.
[http://dx.doi.org/10.1016/j.eururo.2007.06.038] [PMID: 17618043]
[22]
Vasto S, Carruba G, Candore G, Italiano E, Di Bona D, Caruso C. Inflammation and prostate cancer. Future Oncol 2008; 4(5): 637-45.
[http://dx.doi.org/10.2217/14796694.4.5.637] [PMID: 18922121]
[23]
Gurunadha Rao Tunuguntla HS, Evans CP. Management of prostatitis. Prostate Cancer Prostatic Dis 2002; 5(3): 172-9.
[http://dx.doi.org/10.1038/sj.pcan.4500604] [PMID: 12496977]
[24]
Strickler HD, Goedert JJ. Sexual behavior and evidence for an infectious cause of prostate cancer. Epidemiol Rev 2001; 23(1): 144-51.
[http://dx.doi.org/10.1093/oxfordjournals.epirev.a000781] [PMID: 11588840]
[25]
Sarma AV, McLaughlin JC, Wallner LP, et al. Sexual behavior, sexually transmitted diseases and prostatitis: the risk of prostate cancer in black men. J Urol 2006; 176(3): 1108-13.
[http://dx.doi.org/10.1016/j.juro.2006.04.075] [PMID: 16890703]
[26]
Cohen RJ, Shannon BA, McNeal JE, Shannon T, Garrett KL. Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to cancer evolution? J Urol 2005; 173(6): 1969-74.
[http://dx.doi.org/10.1097/01.ju.0000158161.15277.78] [PMID: 15879794]
[27]
Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, Jacobsen SJ. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 2002; 77(3): 219-25.
[http://dx.doi.org/10.4065/77.3.219] [PMID: 11888024]
[28]
Nelson JE, Harris RE. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 2000; 7(1): 169-70.
[http://dx.doi.org/10.3892/or.7.1.169] [PMID: 10601612]
[29]
Norrish AE, Jackson RT, McRae CU. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 1998; 77(4): 511-5.
[http://dx.doi.org/10.1002/(SICI)1097-0215(19980812)77:4<511:AID-IJC6>3.0.CO;2-X] [PMID: 9679750]
[30]
Maitland NJ, Collins AT. Prostate cancer stem cells: a new target for therapy. J Clin Oncol 2008; 26(17): 2862-70.
[http://dx.doi.org/10.1200/JCO.2007.15.1472] [PMID: 18539965]
[31]
Li S, Dai W, Mo W, et al. By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma. Int J Cancer 2017; 141(12): 2571-84.
[http://dx.doi.org/10.1002/ijc.31022] [PMID: 28857200]
[32]
Kutkowska J, Strzadala L, Rapak A. Synergistic activity of sorafenib and betulinic acid against clonogenic activity of non-small cell lung cancer cells. Cancer Sci 2017; 108(11): 2265-72.
[http://dx.doi.org/10.1111/cas.13386] [PMID: 28846180]
[33]
Nam RK, Cheung P, Herschorn S, et al. Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. Lancet Oncol 2014; 15(2): 223-31.
[http://dx.doi.org/10.1016/S1470-2045(13)70606-5] [PMID: 24440474]
[34]
Birkhahn M, Penson DF, Cai J, et al. Long-term outcome in patients with a Gleason score ≤ 6 prostate cancer treated by radical prostatectomy. BJU Int 2011; 108(5): 660-4.
[http://dx.doi.org/10.1111/j.1464-410X.2010.09978.x] [PMID: 21223479]
[35]
Alicikus ZA, Yamada Y, Zhang Z, et al. Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer 2011; 117(7): 1429-37.
[http://dx.doi.org/10.1002/cncr.25467] [PMID: 21425143]
[36]
Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002; 62(4): 1008-13.
[PMID: 11861374]
[37]
Marcelli M, Ittmann M, Mariani S, et al. Androgen receptor mutations in prostate cancer. Cancer Res 2000; 60(4): 944-9.
[PMID: 10706109]
[38]
Haapala K, Hyytinen ER, Roiha M, et al. Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Lab Invest 2001; 81(12): 1647-51.
[http://dx.doi.org/10.1038/labinvest.3780378] [PMID: 11742035]
[39]
Petrylak DP. The current role of chemotherapy in metastatic hormone-refractory prostate cancer. Urology 2005; 65(5): 3-7.
[http://dx.doi.org/10.1016/j.urology.2005.03.053] [PMID: 15885271]
[40]
Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14(6): 1756-64.
[http://dx.doi.org/10.1200/JCO.1996.14.6.1756] [PMID: 8656243]
[41]
Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol 2011; 29(27): 3651-8.
[http://dx.doi.org/10.1200/JCO.2011.35.2005] [PMID: 21859989]
[42]
de Bono JS, Logothetis CJ, Molina A, et al. COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364(21): 1995-2005.
[http://dx.doi.org/10.1056/NEJMoa1014618] [PMID: 21612468]
[43]
Hoffman-Censits J, Kelly WK. Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer. Clin Cancer Res 2013; 19(6): 1335-9.
[http://dx.doi.org/10.1158/1078-0432.CCR-12-2910] [PMID: 23300275]
[44]
Kluetz PG, Pierce W, Maher VE, et al. Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res 2014; 20(1): 9-14.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-2665] [PMID: 24190979]
[45]
Kantoff PW, Higano CS, Shore ND, et al. IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363(5): 411-22.
[http://dx.doi.org/10.1056/NEJMoa1001294] [PMID: 20818862]
[46]
Hurwitz M, Petrylak DP. Sequencing of agents for castration-resistant prostate cancer. Oncology (Williston Park) 2013; 27(11): 1144-1149, 1154-1158.
[PMID: 24575543]
[47]
Attard G, Cooper CS, de Bono JS. Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 2009; 16(6): 458-62.
[http://dx.doi.org/10.1016/j.ccr.2009.11.006] [PMID: 19962664]
[48]
Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68(11): 4447-54.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-0249] [PMID: 18519708]
[49]
Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23(32): 8253-61.
[http://dx.doi.org/10.1200/JCO.2005.03.4777] [PMID: 16278481]
[50]
Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66(5): 2815-25.
[http://dx.doi.org/10.1158/0008-5472.CAN-05-4000] [PMID: 16510604]
[51]
Rayburn ER, Ezell SJ, Zhang R. Anti-Inflammatory Agents for Cancer Therapy. Mol Cell Pharmacol 2009; 1(1): 29-43.
[http://dx.doi.org/10.4255/mcpharmacol.09.05] [PMID: 20333321]
[52]
Climent MA, Pérez-Valderrama B, Mellado B, et al. Weekly cabazitaxel plus prednisone is effective and less toxic for ‘unfit’ metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial. Eur J Cancer 2017; 87: 30-7.
[http://dx.doi.org/10.1016/j.ejca.2017.09.028] [PMID: 29102858]
[53]
Ma Y, Brusselaers N. Maintenance use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk. Prostate Cancer Prostatic Dis 2018; 21(1): 147-52.
[http://dx.doi.org/10.1038/s41391-017-0021-x] [PMID: 29259292]
[54]
Nelles JL, Hu W-Y, Prins GS. Estrogen action and prostate cancer. Expert Rev Endocrinol Metab 2011; 6(3): 437-51.
[http://dx.doi.org/10.1586/eem.11.20] [PMID: 21765856]
[55]
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists’ Collaborative Group. Lancet 2000; 355(9214): 1491-8.
[http://dx.doi.org/10.1016/S0140-6736(00)02163-2] [PMID: 10801170]
[56]
Merseburger AS, Haas GP, von Klot C-A. An update on enzalutamide in the treatment of prostate cancer. Ther Adv Urol 2015; 7(1): 9-21.
[http://dx.doi.org/10.1177/1756287214555336] [PMID: 25642291]
[57]
Semenas J, Dizeyi N, Persson JL. Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer. Drug Des Devel Ther 2013; 875-81.
[http://dx.doi.org/10.2147/DDDT.S45703]
[58]
Fizazi K, Scher HI, Miller K, et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol 2014; 15(10): 1147-56.
[http://dx.doi.org/10.1016/S1470-2045(14)70303-1] [PMID: 25104109]
[59]
Bambury RM, Scher HI. Enzalutamide: Development from bench to bedside. Urol Oncol 2015; 33(6): 280-8.
[http://dx.doi.org/10.1016/j.urolonc.2014.12.017] [PMID: 25797385]
[60]
Joyce R, Fenton MA, Rode P, et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 1998; 159(1): 149-53.
[http://dx.doi.org/10.1016/S0022-5347(01)64039-4] [PMID: 9400459]
[61]
Scher HI, Liebertz C, Kelly WK, et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997; 15(8): 2928-38.
[http://dx.doi.org/10.1200/JCO.1997.15.8.2928] [PMID: 9256137]
[62]
Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993; 149(3): 607-9.
[http://dx.doi.org/10.1016/S0022-5347(17)36163-3] [PMID: 7679759]
[63]
Heidenreich A, Bastian PJ, Bellmunt J, et al. European Association of Urology. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014; 65(2): 467-79.
[http://dx.doi.org/10.1016/j.eururo.2013.11.002] [PMID: 24321502]
[64]
Kreis W, Ahmann FR, Jordan VC, de Haan H, Scott M. Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation. Br J Urol 1988; 62(4): 352-4.
[http://dx.doi.org/10.1111/j.1464-410X.1988.tb04364.x] [PMID: 2973364]
[65]
van Poppel H, Nilsson S. Testosterone surge: rationale for gonadotropin-releasing hormone blockers? Urology 2008; 71(6): 1001-6.
[http://dx.doi.org/10.1016/j.urology.2007.12.070] [PMID: 18407326]
[66]
Pont A, Williams PL, Azhar S, et al. Ketoconazole blocks testosterone synthesis. Arch Intern Med 1982; 142(12): 2137-40.
[http://dx.doi.org/10.1001/archinte.1982.00340250097015] [PMID: 6291475]
[67]
Allan CA, McLachlan RI. Chapter 139-Androgen Deficiency Disordersin Endocrinology: Adult and Pediatric (Seventh Edition) Seventh . Philadelphia: W.B. Saunders In: 2016; pp. 2394-420. e13.
[68]
Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004; 22(6): 1025-33.
[http://dx.doi.org/10.1200/JCO.2004.06.037] [PMID: 15020604]
[69]
Johnson DE, Babaian RJ, von Eschenbach AC, Wishnow KI, Tenney D. Ketoconazole therapy for hormonally refractive metastatic prostate cancer. Urology 1988; 31(2): 132-4.
[http://dx.doi.org/10.1016/0090-4295(88)90036-2] [PMID: 3341098]
[70]
O’Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004; 90(12): 2317-25.
[http://dx.doi.org/10.1038/sj.bjc.6601879] [PMID: 15150570]
[71]
Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26(28): 4563-71.
[http://dx.doi.org/10.1200/JCO.2007.15.9749] [PMID: 18645193]
[72]
Auchus RJ, Yu MK, Nguyen S, Mundle SD. Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer. Oncologist 2014; 19(12): 1231-40.
[http://dx.doi.org/10.1634/theoncologist.2014-0167] [PMID: 25361624]
[73]
Schweizer MT, Antonarakis ES. Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther Adv Urol 2012; 4(4): 167-78.
[http://dx.doi.org/10.1177/1756287212452196] [PMID: 22852027]
[74]
Ang JE, Olmos D, de Bono JS. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer 2009; 100(5): 671-5.
[http://dx.doi.org/10.1038/sj.bjc.6604904] [PMID: 19223900]
[75]
Haidar S, Ehmer PB, Barassin S, Batzl-Hartmann C, Hartmann RW. Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo. J Steroid Biochem Mol Biol 2003; 84(5): 555-62.
[http://dx.doi.org/10.1016/S0960-0760(03)00070-0] [PMID: 12767280]
[76]
Iqw Reports, Ed. Abiraterone acetate (prostate cancer) – Benefit assessment ac-cording to §35a Social Code Book V. Dossier assessmentin Institute for Quality and Efficiency in Health Care (IQWiG, Germany). IQWiG, Germany 2018; 605..
[http://dx.doi.org/10.1016/S0960-0760(03)00070-0] [PMID: 12767280]
[77]
Abiraterone acetate (Zytiga) for the treatment of metastatic prostate cancer: Overview.,inInformed Health Online [In-ternet] Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG),. Cologne, Germany 2006.
[78]
Tilley WD, Buchanan G, Hickey TE, Bentel JM. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996; 2(2): 277-85.
[PMID: 9816170]
[79]
Tannock IF, de Wit R, Berry WR, et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351(15): 1502-12.
[http://dx.doi.org/10.1056/NEJMoa040720] [PMID: 15470213]
[80]
American Cancer Society; Treating prostate cancer. Available on: https://www.cancer.org/cancer/prostate-cancer/treating.htmlAccessed on January 10, 2018.
[81]
Zhu M-L, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 2010; 70(20): 7992-8002.
[http://dx.doi.org/10.1158/0008-5472.CAN-10-0585] [PMID: 20807808]
[82]
Kuroda K, Liu H, Kim S, Guo M, Navarro V, Bander NH. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. Prostate 2009; 69(14): 1579-85.
[http://dx.doi.org/10.1002/pros.21004] [PMID: 19575420]
[83]
Mediavilla-Varela M, Pacheco FJ, Almaguel F, et al. Docetaxel induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75. Mol Cancer 2009; 8(1): 68.
[http://dx.doi.org/10.1186/1476-4598-8-68] [PMID: 19715609]
[84]
Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995; 13(10): 2643-55.
[http://dx.doi.org/10.1200/JCO.1995.13.10.2643] [PMID: 7595719]
[85]
Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2011; 8(1): 12-23.
[http://dx.doi.org/10.1038/nrclinonc.2010.136] [PMID: 20859283]
[86]
Galletti E, Magnani M, Renzulli ML, Botta M. Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. ChemMedChem 2007; 2(7): 920-42.
[http://dx.doi.org/10.1002/cmdc.200600308] [PMID: 17530726]
[87]
de Bono JS, Oudard S, Ozguroglu M, et al. TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376(9747): 1147-54.
[http://dx.doi.org/10.1016/S0140-6736(10)61389-X] [PMID: 20888992]
[88]
Kapoor A, Wu C, Shayegan B, Rybak AP. Contemporary agents in the management of metastatic castration-resistant prostate cancer. Can Urol Assoc J 2016; 10(11-12): E414-23.
[http://dx.doi.org/10.5489/cuaj.4112] [PMID: 28096932]
[89]
Saad F, Winquist E, Hubay S, et al. Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone. Can Urol Assoc J 2016; 10(3-4): 102-9.
[http://dx.doi.org/10.5489/cuaj.3470] [PMID: 27217856]
[90]
Gatmaitan ZC, Arias IM. Structure and function of P-glycoprotein in normal liver and small intestine. Adv Pharmacol 1993; 24: 77-97.
[http://dx.doi.org/10.1016/S1054-3589(08)60934-5] [PMID: 8099292]
[91]
Mita AC, Figlin R, Mita MM. Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer? Clin Cancer Res 2012; 18(24): 6574-9.
[http://dx.doi.org/10.1158/1078-0432.CCR-12-1584] [PMID: 23091116]
[92]
Sargent DJ, Niedzwiecki D, O’Connell MJ, Schilsky RL. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 2001; 345(2): 144-5.
[93]
Aggarwal R, Bryce A, Ryan CJ, et al. A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study. Urol Oncol 2017; 35(4): 149.e7-149.e13.
[http://dx.doi.org/10.1016/j.urolonc.2016.11.005] [PMID: 28161323]
[94]
van Dodewaard-de Jong JM, Santegoets SJ, van de Ven PM, et al. Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells. OncoImmunology 2015; 5(4)e1105431
[http://dx.doi.org/10.1080/2162402X.2015.1105431] [PMID: 27141390]
[95]
Mitoxantrone® Fact Sheet. [Online]. Available on: http://pcfa.org.au/media/333739/Drug-Sheet-13-Mitoxantrone.pdf
[96]
Lubiniecki GM, Berlin JA, Weinstein RB, Vaughn DJ. Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma: results of a meta-analysis. Cancer 2004; 101(12): 2755-9.
[http://dx.doi.org/10.1002/cncr.20673] [PMID: 15536625]
[97]
Eisenberger MA, Simon R, O’Dwyer PJ, Wittes RE, Friedman MA. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 1985; 3(6): 827-41.
[http://dx.doi.org/10.1200/JCO.1985.3.6.827] [PMID: 2409240]
[98]
Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993; 71(3): 1098-109.
[http://dx.doi.org/10.1002/1097-0142(19930201)71:3+<1098::AID CNCR2820711432>3.0.CO;2-G] [PMID: 7679039]
[99]
Minato A, Fujimoto N, Kubo T, Harada S, Akasaka S, Matsumoto T. Efficacy of estramustine phosphate according to risk classification of castration-resistant prostate cancer. Med Oncol 2012; 29(4): 2895-900.
[http://dx.doi.org/10.1007/s12032-012-0178-z] [PMID: 22323054]
[100]
Brady D, Parker CC, O’Sullivan JM. Bone-targeting radiopharmaceuticals including radium-223. Cancer J 2013; 19(1): 71-8.
[http://dx.doi.org/10.1097/PPO.0b013e318282479b] [PMID: 23337760]
[101]
Sartor O, Reid RH, Hoskin PJ, et al. Quadramet 424Sm10/11 Study Group. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004; 63(5): 940-5.
[http://dx.doi.org/10.1016/j.urology.2004.01.034] [PMID: 15134985]
[103]
Guo XE, Ngo B, Modrek AS, Lee W-H. Targeting tumor suppressor networks for cancer therapeutics. Curr Drug Targets 2014; 15(1): 2-16.
[http://dx.doi.org/10.2174/1389450114666140106095151] [PMID: 24387338]
[104]
Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013; 31(4): 412-9.
[http://dx.doi.org/10.1200/JCO.2012.45.0494] [PMID: 23169517]
[105]
Bronte E, Galvano A, Novo G, Russo A. Cardiotoxic Effects of Anti-VEGFR Tyrosine Kinase InhibitorsCardio-Oncology. Boston: Academic Press 2017; pp. 69-89.
[http://dx.doi.org/10.1016/B978-0-12-803547-4.00005-7]
[106]
Michaelson MD, Oudard S, Ou YC, et al. Randomized, placebo controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol 2014; 32(2): 76-82.
[http://dx.doi.org/10.1200/JCO.2012.48.5268] [PMID: 24323035]
[107]
Wang B, Lu D, Xuan M, Hu W. Antitumor effect of sunitinib in human prostate cancer cells functions via autophagy. Exp Ther Med 2017; 13(4): 1285-94.
[http://dx.doi.org/10.3892/etm.2017.4134] [PMID: 28413468]
[108]
Dror Michaelson M, Regan MM, Oh WK, et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009; 20(5): 913-20.
[http://dx.doi.org/10.1093/annonc/mdp111] [PMID: 19403935]
[109]
Sheikh NA, Petrylak D, Kantoff PW, et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother 2013; 62(1): 137-47.
[http://dx.doi.org/10.1007/s00262-012-1317-2] [PMID: 22865266]
[110]
Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 2011; 17(11): 3520-6.
[http://dx.doi.org/10.1158/1078-0432.CCR-10-3126] [PMID: 21471425]
[111]
Sipuleucel-T (Provenge) for metastatic prostate cancer: Over-view, Informed Health Online [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG), 2006. [Online]. Available on : https://www.ncbi.nlm.nih.gov/books/NBK284965/
[112]
Graff JN, Chamberlain ED. Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy. Core Evid 2014; 10: 1-10.
[http://dx.doi.org/10.2147/CE.S54712] [PMID: 25565923]
[113]
Lee C-H, Kantoff P. Treatment of metastatic prostate cancer in 2018. JAMA Oncol 2019; 5(2): 263-4.
[114]
Newman DJ, Cragg GM. Natural Products as Sources of New Drugs from 1981 to 2014. J Nat Prod 2016; 79(3): 629-61.
[http://dx.doi.org/10.1021/acs.jnatprod.5b01055] [PMID: 26852623]
[115]
Chin Y-W, Yoon KD, Kim J. Cytotoxic anticancer candidates from terrestrial plants. Anticancer Agents Med Chem 2009; 9(8): 913-42.
[http://dx.doi.org/10.2174/187152009789124664] [PMID: 19663789]
[116]
Mangal M, Sagar P, Singh H, Raghava GPS, Agarwal SM. NPACT: Naturally Occurring Plant-based Anti-cancer Compound-Activity-Target database. Nucleic Acids Res 2013; 41: D1124-9.
[http://dx.doi.org/10.1093/nar/gks1047]
[117]
Cordell GA. PC-SPES: a brief overview. Integr Cancer Ther 2002; 1(3): 271-86.
[http://dx.doi.org/10.1177/153473540200100312] [PMID: 14667285]
[118]
Eid SY, El-Readi MZ, Fatani SH, Eldin EEMN, Wink M. Natural products modulate the multifactorial multidrug resistance of cancer. Pharmacol Pharm 2015; 6: 146-76.
[http://dx.doi.org/10.4236/pp.2015.63017]
[119]
Torquato HFV, Goettert MI, Justo GZ, Paredes-Gamero EJ. Anti-cancer phytometabolites targeting cancer stem cells. Curr Genomics 2017; 18(2): 156-74.
[http://dx.doi.org/10.2174/1389202917666160803162309] [PMID: 28367074]
[120]
Liu T, Ma M, Ge H-M, Yang C, Cleveland J, Shen B. Synthesis and evaluation of 8,4′-dideshydroxy-leinamycin revealing new insights into the structure-activity relationship of the anticancer natural product leinamycin. Bioorg Med Chem Lett 2015; 25(21): 4899-902.
[http://dx.doi.org/10.1016/j.bmcl.2015.05.078] [PMID: 26071634]
[121]
Yue Z, Zhang W, Lu Y, et al. Prediction of cancer cell sensitivity to natural products based on genomic and chemical properties. PeerJ 2015; 3e1425
[http://dx.doi.org/10.7717/peerj.1425] [PMID: 26644976]
[122]
Colegate SM, Molyneux RJ. Bioactive natural products: detection, isolation and structural determination. Second edition. CRC Press 2007.
[123]
Dostál V, Libusová L. Microtubule drugs: action, selectivity, and resistance across the kingdoms of life. Protoplasma 2014; 251(5): 991-1005.
[http://dx.doi.org/10.1007/s00709-014-0633-0] [PMID: 24652407]
[124]
Grytli HH, Fagerland MW, Fosså SD, Taskén KA. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol 2014; 65(3): 635-41.
[http://dx.doi.org/10.1016/j.eururo.2013.01.007] [PMID: 23351721]
[125]
Lu H, Liu X, Guo F, et al. Impact of beta-blockers on prostate cancer mortality: a meta-analysis of 16,825 patients. OncoTargets Ther 2015; 8: 985-90.
[http://dx.doi.org/10.2147/OTT.S78836] [PMID: 25995645]
[126]
Magnon C, Hall SJ, Lin J, et al. Autonomic nerve development contributes to prostate cancer progression. Science 2013; 341(6142)1236361
[http://dx.doi.org/10.1126/science.1236361] [PMID: 23846904]
[127]
Zahalka AH, Arnal-Estapé A, Maryanovich M, et al. Adrenergic nerves activate an angio-metabolic switch in prostate cancer. Science 2017; 358(6361): 321-6.
[http://dx.doi.org/10.1126/science.aah5072] [PMID: 29051371]
[128]
Wang S, Gao D, Chen Y. The potential of organoids in urological cancer research. Nat Rev Urol 2017; 14(7): 401-14.
[http://dx.doi.org/10.1038/nrurol.2017.65] [PMID: 28534535]
[129]
Lunardi A, Ala U, Epping MT, et al. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet 2013; 45(7): 747-55.
[http://dx.doi.org/10.1038/ng.2650] [PMID: 23727860]
[130]
Dutta A, Panja S, Virk RK, et al. Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition. Eur Urol 2017; 72(4): 499-506.
[http://dx.doi.org/10.1016/j.eururo.2017.03.031] [PMID: 28385453]
[131]
Arriaga JM, Abate-Shen C. Genetically engineered mouse models of prostate cancer in the postgenomic era. Cold Spring Harb Perspect Med 2019; 9(2): pii: a030528
[http://dx.doi.org/10.1101/cshperspect.a030528] [PMID: 29661807]
[132]
Lin D, Wyatt AW, Xue H, et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res 2014; 74(4): 1272-83.
[http://dx.doi.org/10.1158/0008-5472.CAN-13-2921-T] [PMID: 24356420]
[133]
Tentler JJ, Tan AC, Weekes CD, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 2012; 9(6): 338-50.
[http://dx.doi.org/10.1038/nrclinonc.2012.61] [PMID: 22508028]
[134]
Aparicio S, Hidalgo M, Kung AL. Examining the utility of patient-derived xenograft mouse models. Nat Rev Cancer 2015; 5: 311-6.
[http://dx.doi.org/10.1038/nrc3944]
[135]
Wang G, Zhao D, Spring DJ, DePinho RA. Genetics and biology of prostate cancer. Genes Dev 2018; 32: 1105-40.
[http://dx.doi.org/10.1101/gad.315739.118] [PMID: 30181359]
[136]
Cheon D-J, Orsulic S. Mouse models of cancer. Annu Rev Pathol 2011; 6: 95-119.
[http://dx.doi.org/10.1146/annurev.pathol.3.121806.154244] [PMID: 20936938]
[137]
Clevers H. Modeling Development and Disease with Organoids. Cell 2016; 165(7): 1586-97.
[http://dx.doi.org/10.1016/j.cell.2016.05.082] [PMID: 27315476]
[138]
Risbridger GP, Toivanen R, Taylor RA. Preclinical models of prostate cancer: patient-derived xenografts, organoids, and other explant models. Cold Spring Harb Perspect Med 2018; 8(8): pii: a030536
[http://dx.doi.org/10.1101/cshperspect.a030536] [PMID: 29311126]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 3
Year: 2020
Published on: 14 October, 2020
Page: [168 - 180]
Pages: 13
DOI: 10.2174/1574885514666190917150635
Price: $65

Article Metrics

PDF: 23
HTML: 2
EPUB: 1
PRC: 1